Home > Insider Trading > Filing (0001209191-20-063615)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1662774	Cortexyme Inc.	CRTX	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1770821	Leslie Holsinger	C/O Cortexyme, Inc. 269 East Grand Ave. South San Francisco CA 94080	Executive Vice President	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-14	40,000	$0.27	43,500	No	4	M	Direct
Common Stock	Disposition	2020-12-14	1,700	$28.80	41,800	No	4	S	Direct
Common Stock	Disposition	2020-12-14	14,275	$30.15	27,525	No	4	S	Direct
Common Stock	Disposition	2020-12-14	13,200	$30.91	14,325	No	4	S	Direct
Common Stock	Disposition	2020-12-14	9,525	$31.79	1,800	No	4	S	Direct
Common Stock	Disposition	2020-12-14	400	$32.59	4,400	No	4	S	Direct
Common Stock	Disposition	2020-12-14	900	$32.59	3,500	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2020-12-11	100,000	$0.00	100,000	$29.60
Common Stock	Stock Option (Right to Buy)	Acquisiton	2020-12-11	100,000	$0.00	100,000	$29.60
Common Stock	Stock Option (Right to Buy)	Disposition	2020-12-14	40,000	$0.00	40,000	$0.27

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
100,000	2030-12-10	No	4	A	Direct
100,000	2030-12-10	No	4	A	Direct
66,794	2026-05-09	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 29, 2020.
The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date.
50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share.
The option vested at the rate of 25% of the shares on April 4, 2017, and the remaining 75% of shares vested in equal monthly installments beginning on May 4, 2017 until all the shares were fully vested on April 4, 2020.